表紙:良性前立腺肥大症治療薬市場 - 治療薬クラス別、治療タイプ別:世界の機会分析と業界予測(2021年~2030年)
市場調査レポート
商品コード
1065610

良性前立腺肥大症治療薬市場 - 治療薬クラス別、治療タイプ別:世界の機会分析と業界予測(2021年~2030年)

Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class and Therapy Type : Global Opportunity Analysis and Industry Forecast, 2021-2030

出版日: | 発行: Allied Market Research | ページ情報: 英文 216 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
良性前立腺肥大症治療薬市場 - 治療薬クラス別、治療タイプ別:世界の機会分析と業界予測(2021年~2030年)
出版日: 2022年01月25日
発行: Allied Market Research
ページ情報: 英文 216 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の良性前立腺肥大症治療薬の市場規模は、2020年には56億9,770万米ドルとなりました。

同市場は、2021年~2030年にかけて5.00%のCAGRで拡大し、2030年には93億9,150万米ドルに達すると予測されています。

この疾患は一般的に50歳以上の男性に発症するため、高齢男性の人口が増加することが同市場の主な要因となっています。その他、人口の不健康なライフスタイルの増加、泌尿器科疾患に対する意識の高まり、病状の早期診断、前立腺癌の増加、世界の前立腺肥大症患者数の増加などが、同市場の成長を後押ししています。

当レポートでは、世界の良性前立腺肥大症治療薬市場について調査し、市場の概要とともに、治療薬クラス別、治療タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主な調査結果
  • ポーターのファイブフォース分析
  • 主要参入企業の位置づけ、2020年
  • 市場力学
    • 促進要因
      • 高齢者人口の増加
      • 良性前立腺肥大症の有病率の急増
      • 泌尿器疾患に対する意識の高まり
      • 世界中でのヘルスケア費の急増
    • 抑制要因
      • 低侵襲性外科治療に対する傾倒
    • 市場の機会
      • パイプラインに存在する多数の製品
      • 新興市場での有利な機会
  • 影響分析
  • 良性前立腺肥大症治療薬市場に対するCOVID-19の影響分析
  • 臨床試験分析、2019年~2022年

第4章 良性前立腺肥大症治療薬市場:治療薬クラス別

  • 概要
    • 市場規模と予測
  • アルファ遮断薬
  • 5-アルファ還元酵素阻害剤
  • ホスホジエステラーゼ-5阻害剤
  • その他

第5章 良性前立腺肥大症治療薬市場:治療タイプ別

  • 概要
    • 市場規模と予測
  • 単剤療法
  • 併用薬療法

第6章 良性前立腺肥大症治療薬市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主要な市場動向、成長促進要因、および機会
    • 北米の良性前立腺肥大症治療薬市場:治療薬クラス別
    • 北米の良性前立腺肥大症治療薬市場:治療タイプ別
    • 市場規模と予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主要な市場動向、成長促進要因、および機会
    • 欧州の良性前立腺肥大症治療薬市場:治療薬クラス別
    • 欧州の良性前立腺肥大症治療薬市場:治療タイプ別
    • 市場規模と予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他
  • アジア太平洋
    • 主要な市場動向、成長促進要因、および機会
    • アジア太平洋の良性前立腺肥大症治療薬市場:治療薬クラス別
    • アジア太平洋の良性前立腺肥大症治療薬市場:治療法別
    • 市場規模と予測:国別
      • 日本
      • 中国
      • オーストラリア
      • インド
      • 韓国
      • その他
  • ラテンアメリカ、中東、アフリカ
    • 主要な市場動向、成長促進要因、および機会
    • ラテンアメリカ、中東、アフリカの良性前立腺肥大症治療薬市場:治療薬クラス別
    • ラテンアメリカ、中東、アフリカの良性前立腺肥大症治療薬市場:治療タイプ別
    • ラテンアメリカ、中東、アフリカの良性前立腺肥大症治療薬市場:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ
      • その他

第7章 企業プロファイル

  • ABBOTT LABORATORIES
  • ABBVIE INC.(ALLERGAN INC.)
  • ASTELLAS PHARMA INC.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE PLC.
  • MERCK & CO. INC.(MERCK SHARP & DOHME CORP.)
  • PFIZER INC.
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
図表

LIST OF TABLES

  • TABLE 01.BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY CLINICAL TRIALS
  • TABLE 02.BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 03.ALPHA BLOCKERS MARKET, BY REGION, 2021-2030 ($MILLION)
  • TABLE 04.5- ALPHA REDUCTASE INHIBITORS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.PHOSPHODIESTERASE-5 INHIBITORS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.OTHERS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 08.MONO DRUG THERAPY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.COMBINATION DRUG THERAPY, BY REGION, 2020-2030($MILLION)
  • TABLE 10.BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 12.NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 13.NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 14.U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 15.U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 16.CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 17.CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 18.MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 19.MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 20.EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 21.EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 22.EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 23.GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 24.GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 25.FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 26.FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 27.UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 28.UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 29.ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 30.ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 31.SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 32.SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 33.REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 34.REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 35.ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 36.ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 37.ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 38.JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 39.JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 40.CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 41.CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 42.AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 43.AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 44.INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 45.INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 46.SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 47.SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 48.REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 49.REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 50.LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 51.LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 52.LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 53.BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 54.BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 55.SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 56.SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 57.SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 58.SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 59.REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
  • TABLE 60.REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
  • TABLE 61.ABBOTT: COMPANY SNAPSHOT
  • TABLE 62.ABBOTT: OPERATING SEGMENTS
  • TABLE 63.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 64.ABBVIE: COMPANY SNAPSHOT
  • TABLE 65.ABBVIE: PRODUCT SEGMENT
  • TABLE 66.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 67.ASTELLAS: COMPANY SNAPSHOT
  • TABLE 68.ASTELLAS: OPERATING SEGMENTS
  • TABLE 69.ASTELLAS: PRODUCT PORTFOLIO
  • TABLE 70.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 71.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 72.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 73.LILLY: COMPANY SNAPSHOT
  • TABLE 74.LILLY: OPERATING SEGMENTS
  • TABLE 75.LILLY: PRODUCT PORTFOLIO
  • TABLE 76.GSK: COMPANY SNAPSHOT
  • TABLE 77.GSK: PRODUCT SEGMENTS
  • TABLE 78.GSK: PRODUCT PORTFOLIO
  • TABLE 79.MERCK: COMPANY SNAPSHOT
  • TABLE 80.MERCK: OPERATING SEGMENTS
  • TABLE 81.MERCK: PRODUCT PORTFOLIO
  • TABLE 82.PFIZER: COMPANY SNAPSHOT
  • TABLE 83.PFIZER: OPERATING BUSINESS SEGMENT
  • TABLE 84.PFIZER: PRODUCT PORTFOLIO
  • TABLE 85.SANOFI: COMPANY SNAPSHOT
  • TABLE 86.SANOFI: OPERATING SEGMENTS
  • TABLE 87.SANOFI: PRODUCT TYPE PORTFOLIO
  • TABLE 88.TEVA: COMPANY SNAPSHOT
  • TABLE 89.TEVA: OPERATING SEGMENTS
  • TABLE 90.TEVA: PRODUCT PORTFOLIO
  • TABLE 91.TEVA: KEY DEVELOPMENT

LIST OF FIGURES

  • FIGURE 01.GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 05.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 06.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 07.MODERATE INTENSITY OF RIVALRY
  • FIGURE 08.TOP PLAYER POSITIONING, 2020
  • FIGURE 09.IMPACT ANALYSIS
  • FIGURE 10.COMPARATIVE ANALYSIS OF ALPHA BLOCKERS MARKET, BY COUNTRY, 2021-2030 (%)
  • FIGURE 11.COMPARATIVE ANALYSIS OF 5- ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 12.COMPARATIVE ANALYSIS OF PHOSPHODIESTERASE-5 INHIBITORS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 13.COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2020-2030 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF MONO DRUG THERAPY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF COMBINATION DRUG THERAPY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 16.ABBOTT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 17.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 18.ABBOTT: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 19.ABBVIE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 20.ABBVIE: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 21.ASTELLAS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 22.ASTELLAS: REVENUE SHARE, BY SEGMENTS, 2020 (%)
  • FIGURE 23.ASTELLAS: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 24.BOEHRINGER INGELHEIM: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENTS, 2020 (%)
  • FIGURE 26.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 27.LILLY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.LILLY: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 29.GSK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 30.GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 31.GSK: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 32.MERCK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 33.MERCK: REVENUE SHARE, BY SEGMENTS, 2020 (%)
  • FIGURE 34.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 35.PFIZER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 37.SANOFI: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 38.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 39.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 40.TEVA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 41.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 42.TEVA: REVENUE SHARE BY REGION, 2020(%)
目次
Product Code: LI_184708 / A04353

The global benign prostatic hyperplasia therapeutics market was valued at $5,697.70 million in 2020, and is estimated to reach $9,391.50 million by 2030, growing at a CAGR of 5.00% from 2021 to 2030.

The prostate is a walnut-sized gland that surrounds the urethra in the male reproductive system. The main function of this gland is to secrete a fluid, which mixes with the fluids from other glands and sperm cells from the testicles to generate semen. Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland. It is also called benign prostatic hypertrophy or benign prostatic obstruction. As a man gets older, his prostate goes through two major growth stages. The first happens when the prostate doubles in size throughout adolescence. The second stage of development begins at the age of 25 and lasts for the rest of a man's life. The BPH is common during the second growth phase.

As the prostate gland grows larger, it presses against and pinches the urethra. The bladder's lining thickens. It prevents urine from flowing freely from the bladder, resulting in nighttime urination, urinary hesitation, trouble starting to urinate, a weak urine stream or a stream that stops and begins, dribbling at the end of urination, and a sense of urgency to urinate. The bladder's ability to empty completely may weaken over time, causing urinary retention by leaving some urine in the bladder. Many of the symptoms of benign prostatic hyperplasia are caused by urethral constriction and urine retention, or the inability to empty the bladder entirely. Because of symptoms like urine leakage and nocturia, BPH has a substantial impact on the patient's quality of life. If untreated for a long duration, it results in more serious health issues, such as bladder damage, bladder stones, kidney damage, and urinary tract infections (UTIs). Moreover, lower urinary tract symptoms (LUTS) are becoming more common in both men and women as they get older. LUTS is frequently associated with benign prostatic hyperplasia in men (BPH).

This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 50 and above. For instance, according to The Administration for Community Living, which includes the Administration on Aging, is an operating division of the U.S. Department of Health and Human Services. In 2019, the American population aged above 65 was 54.1 million among which about 24.1million were men. The overall population aged 65 and older increased from 39.6 million in 2009 to 54.1 million in 2019 a 36% increase and is projected to reach 94.7 million in 2060. By 2040, there will be about 80.8 million older persons, more than twice as many as in 2000. Thus, such increase in older population especially in males is anticipated to drive the growth of the market. In addition, according to The Official Foundation of the American Urological Association about half of all men aged between 51 and 60 years and up to 90% of men over age 80 have BPH.

The other factors boosting the market growth include increase in unhealthy lifestyle among the population, growth in awareness related to urological disorders, early diagnosis of the medical condition, rise in prostate cancer cases and rise in the number of global benign prostatic hyperplasia patients. In addition, a family history of erectile dysfunction, obesity, type 2 diabetes, insufficient exercise, and erectile dysfunction are all risk factors of BPH. The alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor therapeutic class of drugs are the majorly used. Furthermore, antimuscarinics, anticholinergic agents, and beta 3 adrenoreceptor are also used.

However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.

The global benign prostatic hyperplasia therapeutics market is segmented on the basis of therapeutic class, therapy, and region. On the basis of therapeutic class, the market is categorized into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. By therapy, the market is bifurcated into mono drug therapy and combination drug therapy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).

The major players profiled in the report are Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global benign prostatic hyperplasia therapeutics market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

  • #By Therapeutics Class
  • ## Alpha blockers
  • ## 5- alpha reductase inhibitors
  • ## Phosphodiesterase-5 inhibitors
  • ##Others
  • #By Therapy
  • ## Mono drug therapy
  • ## Combination drug therapy
  • #By Region
  • ##North America
  • ###U.S.
  • ###Canada
  • ###Mexico
  • ##Europe
  • ###UK
  • ###Germany
  • ###France
  • ###Spain
  • ###Italy
  • ###Rest of Europe
  • ##Asia-Pacific
  • ###China
  • ###Japan
  • ###India
  • ###Australia
  • ###South Korea
  • ###Rest of Asia-Pacific
  • ##LAMEA
  • ###Brazil
  • ###South Africa
  • ###Saudi Arabia
  • ### Rest of LAMEA
  • # KEY MARKET PLAYERS
  • ## Abbott Laboratories
  • ## AbbVie (Allergan Plc)
  • ## Astellas Pharma Inc.
  • ## Boehringer Ingelheim Pharma GmbH & Co. KG
  • ## Eli Lilly and Company
  • ## GlaxoSmithKline plc.
  • ## Merck & Co., Inc. (Merck Sharp & Dohme Corp)
  • ## Pfizer Inc.
  • ## Sanofi
  • ## Teva Pharmaceutical Industries Limited

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profile in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in geriatric population
      • 3.5.1.2.Surge in prevalence of benign prostatic hyperplasia
      • 3.5.1.3.Increase in awareness toward urological disorders
      • 3.5.1.4.Surge in healthcare expenditure worldwide
    • 3.5.2.Restraint
      • 3.5.2.1.High preference for minimally invasive surgical therapies
    • 3.5.3.Opportunities
      • 3.5.3.1.Large number of products in pipeline
      • 3.5.3.2.Lucrative opportunities in emerging markets
  • 3.6.Impact analysis
  • 3.7.Impact analysis of COVID-19 on the benign prostatic hyperplasia therapeutics market
  • 3.8.Clinical trials analysis, 2019-2022

CHAPTER 4:BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Alpha blockers
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.5- alpha reductase inhibitors
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Phosphodiesterase-5 inhibitors
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Others
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country

CHAPTER 5:BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Mono drug therapy
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Combination drug therapy
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.North America benign prostatic hyperplasia therapeutics market, by therapeutic class
    • 6.2.3.North America benign prostatic hyperplasia therapeutics market, by therapy
    • 6.2.4.Market size and forecast, by country
      • 6.2.4.1.U.S.
      • 6.2.4.1.1.U.S. benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.2.4.1.2.U.S. benign prostatic hyperplasia therapeutics market, by therapy
      • 6.2.4.2.Canada
      • 6.2.4.2.1.Canada benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.2.4.2.2.Canada benign prostatic hyperplasia therapeutics market, by therapy
      • 6.2.4.3.Mexico
      • 6.2.4.3.1.Mexico benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.2.4.3.2.Mexico benign prostatic hyperplasia therapeutics market, by therapy
  • 6.3.Europe
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Europe benign prostatic hyperplasia therapeutics market, by therapeutic class
    • 6.3.3.Europe benign prostatic hyperplasia therapeutics market, by therapy
    • 6.3.4.Market size and forecast, by country
      • 6.3.4.1.Germany
      • 6.3.4.1.1.Germany benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.3.4.1.2.Germany benign prostatic hyperplasia therapeutics market, by therapy
      • 6.3.4.2.France
      • 6.3.4.2.1.France benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.3.4.2.2.France benign prostatic hyperplasia therapeutics market, by therapy
      • 6.3.4.3.UK
      • 6.3.4.3.1.UK benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.3.4.3.2.UK benign prostatic hyperplasia therapeutics market, by therapy
      • 6.3.4.4.Italy
      • 6.3.4.4.1.Italy benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.3.4.4.2.Italy benign prostatic hyperplasia therapeutics market, by therapy
      • 6.3.4.5.Spain
      • 6.3.4.5.1.Spain benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.3.4.5.2.Spain benign prostatic hyperplasia therapeutics market, by therapy
      • 6.3.4.6.Rest of Europe
      • 6.3.4.6.1.Rest of Europe benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.3.4.6.2.Rest of Europe benign prostatic hyperplasia therapeutics market, by therapy
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapeutic class
    • 6.4.3.Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapy
    • 6.4.4.Market size and forecast, by country
      • 6.4.4.1.Japan
      • 6.4.4.1.1.Japan benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.4.4.1.2.Japan benign prostatic hyperplasia therapeutics market, by therapy
      • 6.4.4.2.China
      • 6.4.4.2.1.China benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.4.4.2.2.China benign prostatic hyperplasia therapeutics market, by therapy
      • 6.4.4.3.Australia
      • 6.4.4.3.1.Australia benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.4.4.3.2.Australia benign prostatic hyperplasia therapeutics market, by therapy
      • 6.4.4.4.India
      • 6.4.4.4.1.India benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.4.4.4.2.India benign prostatic hyperplasia therapeutics market, by therapy
      • 6.4.4.5.South Korea
      • 6.4.4.5.1.South Korea benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.4.4.5.2.South Korea benign prostatic hyperplasia therapeutics market, by therapy
      • 6.4.4.6.Rest of Asia-Pacific
      • 6.4.4.6.1.Rest of Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.4.4.6.2.Rest of Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapy
  • 6.5.LAMEA
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.LAMEA benign prostatic hyperplasia therapeutics market, by therapeutic class
    • 6.5.3.LAMEA benign prostatic hyperplasia therapeutics market, by therapy
    • 6.5.4.LAMEA benign prostatic hyperplasia therapeutics market, by country
      • 6.5.4.1.Brazil
      • 6.5.4.1.1.Brazil benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.5.4.1.2.Brazil benign prostatic hyperplasia therapeutics market, by therapy
      • 6.5.4.2.Saudi Arabia
      • 6.5.4.2.1.Saudi Arabia benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.5.4.2.2.Saudi Arabia benign prostatic hyperplasia therapeutics market, by therapy
      • 6.5.4.3.South Africa
      • 6.5.4.3.1.South Africa benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.5.4.3.2.South Africa benign prostatic hyperplasia therapeutics market, by therapy
      • 6.5.4.4.Rest of LAMEA
      • 6.5.4.4.1.Rest of LAMEA benign prostatic hyperplasia therapeutics market, by therapeutic class
      • 6.5.4.4.2.Rest of LAMEA benign prostatic hyperplasia therapeutics market, by therapy

CHAPTER 7:COMPANY PROFILES

  • 7.1.ABBOTT LABORATORIES
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
  • 7.2.ABBVIE INC. (ALLERGAN INC.)
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product portfolio
    • 7.2.5.Business performance
  • 7.3.ASTELLAS PHARMA INC.
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
  • 7.4.BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
  • 7.5.ELI LILLY AND COMPANY
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
  • 7.6.GLAXOSMITHKLINE PLC.
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
  • 7.7.MERCK & CO. INC. (MERCK SHARP & DOHME CORP.)
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
  • 7.8.PFIZER INC.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
  • 7.9.SANOFI
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
  • 7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
    • 7.10.6.Key strategic moves and developments